2017-18 HSC Section 4 Green Book

HY P E R TROP H I C S CAR S AND K E LO I D S

35. D ’ Andrea F, Brongo S, Ferraro G, Baroni A. Prevention and treatment of keloids with intralesional verapamil. Dermatology 2002;204:60 – 2. 36. Copcu E, Sivrioglu N, Oztan Y. Combination of surgery and intralesional verapamil injection in the treatment of the keloid. J Burn Care Rehabil 2004;25:1 – 7. 37. Skaria AM. Prevention and treatment of keloids with intralesional verapamil. Dermatology 2004;209:71. 38. Margaret Shanthi FX, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol 2008;74:343 – 8. 39. Ahuja RB, Chatterjee P. Comparative ef fi cacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. Burns 2014;40:583 – 8. 40. Boggio RF, Boggio LF, Galvao BL, Machado-Santelli GM. Topical verapamil as a scar modulator. Aesthetic Plast Surg 2014;38:968 – 75. 41. Kato M, Dote K, Sasaki S, Takemoto H, et al. Intracoronary verapamil rapidly terminates reperfusion tachyarrhythmias in acute myocardial infarction. Chest 2004;126:702 – 8. 42. Bergson P, Lipkind G, Lee SP, Duban ME, et al. Verapamil block of T-type calcium channels. Mol Pharmacol 2011;79:411 – 9. 43. Aggeler J, Frisch SM, Werb Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fi broblasts. J Cell Biol 1984;98:1662 – 71. 44. Aggeler J. Cytoskeletal dynamics in rabbit synovial fi broblasts: II. Reformation of stress fi bers in cells rounded by treatment with collagenase-inducing agents. Cell Motil Cytoskeleton 1990;16: 121 – 32. 45. van der Wal MB, Verhaegen PD, Middelkoop E, van Zuijlen PP. A clinimetric overview of scar assessment scales. J Burn Care Res 2012; 33:e79 – 87. 46. Draaijers LJ, Tempelman FR, Botman YA, Tuinebreijer WE, et al. The patient and observer scar assessment scale: a reliable and feasible tool for scar evaluation. Plast Reconstr Surg 2004;113:1960 – 5; discussion 6 – 7. 47. Fearmonti R, Bond J, Erdmann D, Levinson H. A review of scar scales and scar measuring devices. Eplasty 2010;10:e43. 48. Nedelec B, Shankowsky HA, Tredget EE. Rating the resolving hypertrophic scar: comparison of the Vancouver Scar Scale and scar volume. J Burn Care Rehabil 2000;21:205 – 12. 49. Lau JC, Li-Tsang CW, Zheng YP. Application of tissue ultrasound palpation system (TUPS) in objective scar evaluation. Burns 2005;31: 445 – 52. 50. Taylor B, McGrouther DA, Bayat A. Use of a non-contact 3D digitiser to measure the volume of keloid scars: a useful tool for scar assessment. J Plast Reconstr Aesthet Surg 2007;60:87 – 94. 51. Ardehali B, Nouraei SA, Van Dam H, Dex E, et al. Objective assessment of keloid scars with three-dimensional imaging: quantifying response to intralesional steroid therapy. Plast Reconstr Surg 2007;119:556 – 61.

17. Camacho-Martinez FM, Rey ER, Serrano FC, Wagner A. Results of a combination of bleomycin and triamcinolone acetonide in the treatment of keloids and hypertrophic scars. An Bras Dermatol 2013; 88:387 – 94. 18. Sadeghinia A, Sadeghinia S. Comparison of the ef fi cacy of intralesional triamcinolone acetonide and 5- fl uorouracil tattooing for the treatment of keloids. Dermatol Surg 2012;38:104 – 9. 19. Emad M, Omidvari S, Dastgheib L, Mortazavi A, et al. Surgical excision and immediate postoperative radiotherapy versus cryotherapy and intralesional steroids in the management of keloids: a prospective clinical trial. Med Princ Pract 2010;19:402 – 5. 20. McCoy BJ, Diegelmann RF, Cohen IK. In vitro inhibition of cell growth, collagen synthesis, and prolyl hydroxylase activity by triamcinolone acetonide. Proc Soc Exp Biol Med 1980;163:216 – 22. 21. Cruz NI, Korchin L. Inhibition of human keloid fi broblast growth by isotretinoin and triamcinolone acetonide in vitro. Ann Plast Surg 1994; 33:401 – 5. 22. Boyadjiev C, Popchristova E, Mazgalova J. Histomorphologic changes in keloids treated with Kenacort. J Trauma 1995;38:299 – 302. 23. Anthony ET, Lemonas P, Navsaria HA, Moir GC. The cost effectiveness of intralesional steroid therapy for keloids. Dermatol Surg 2010;36:1624 – 6. 24. Lee RC, Doong H, Jellema AF. The response of burn scars to intralesional verapamil. Report of fi ve cases. Arch Surg 1994;129:107 – 11. 25. Trisliana Perdanasari A, Lazzeri D, Su W, Xi W, et al. Recent developments in the use of intralesional injections keloid treatment. Arch Plast Surg 2014;41:620 – 9. 26. Liberati A, Altman DG, Tetzlaff J, Mulrow C, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65 – 94. 27. Oxford Centre for Evidence-Based Medicine, Levels of Evidence 2009. Available from: http://www.cebm.net. Accessed October 12, 2014. 28. Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990;49:463 – 6. 29. Doong H, Dissanayake S, Gowrishankar TR, LaBarbera MC, et al. The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce 30. Xue H, McCauley RL, Zhang W. Elevated interleukin-6 expression in keloid fi broblasts. J Surg Res 2000;89:74 – 7. 31. Giugliano G, Pasquali D, Notaro A, Brongo S, et al. Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fi broblasts. Br J Plast Surg 2003;56:804 – 9. 32. Yang JY, Huang CY. The effect of combined steroid and calcium channel blocker injection on human hypertrophic scars in animal model: a new strategy for the treatment of hypertrophic scars. Dermatol Surg 2010;36:1942 – 9. 33. Boggio RF, Freitas VM, Cassiola FM, Urabayashi M, et al. Effect of a calcium-channel blocker (verapamil) on the morphology, cytoskeleton and collagenase activity of human skin fi broblasts. Burns 2011;37:616 – 25. 34. Lawrence WT. Treatment of earlobe keloids with surgery plus adjuvant intralesional verapamil and pressure earrings. Ann Plast Surg 1996;37: 167 – 9. procollagenase synthesis in keloid and normal human dermal fi broblasts. J Burn Care Rehabil 1996;17(6 Pt 1):497 – 514.

Address correspondence and reprint requests to: Svenna Verhiel, MD, Department of Plastic, Reconstructive and Hand Surgery, Rooseveltlaan 211-1, 1079AS Amsterdam, the Netherlands, or e-mail: svenna3@hotmail.com

DE RMATOLOG I C S URG E RY

204